Vyant Bio (NASDAQ:VYNT) PT Lowered to $3.00 at HC Wainwright

Vyant Bio (NASDAQ:VYNTGet Rating) had its target price lowered by equities research analysts at HC Wainwright to $3.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 338.34% from the company’s current price.

Separately, Zacks Investment Research downgraded shares of Vyant Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th.

Shares of NASDAQ VYNT traded up $0.00 during trading hours on Tuesday, hitting $0.68. 500 shares of the company’s stock were exchanged, compared to its average volume of 51,028. The company’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.38. Vyant Bio has a 1-year low of $0.64 and a 1-year high of $4.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.27 and a quick ratio of 4.19.

Several hedge funds and other institutional investors have recently modified their holdings of VYNT. Geode Capital Management LLC boosted its holdings in Vyant Bio by 6.9% during the third quarter. Geode Capital Management LLC now owns 188,802 shares of the company’s stock valued at $439,000 after purchasing an additional 12,122 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Vyant Bio in the third quarter valued at $254,000. Virtu Financial LLC bought a new position in shares of Vyant Bio during the fourth quarter valued at $64,000. Morgan Stanley boosted its stake in shares of Vyant Bio by 14,258.1% in the 2nd quarter. Morgan Stanley now owns 38,049 shares of the company’s stock valued at $142,000 after purchasing an additional 37,784 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Vyant Bio in the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 8.71% of the company’s stock.

Vyant Bio Company Profile (Get Rating)

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.